E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Psycosis associated to Parkinson's Disease |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10027361 |
E.1.2 | Term | Mental disorders due to a general medical condition NEC |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the long-term safety and effectiveness of melperone in open-label studies in treating patients with psychosis associated with Parkinsons Disease |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1. Patients and/or their legally authorised representative (LAR) must have signed and dated the Informed Consent Form approved by the Ethics Committee of the structure where they are cured; 2. Participation in the previous Ovation sponsored study on the psychosis of Parkinsons Disease with melperone. |
|
E.4 | Principal exclusion criteria |
1. Patients remaining more than 14 days without treatment from when the last dose of the experimental medication was taken in the previous Ovation sponsored study on psychosis in PD; 2. Patients having serious or severe adverse effects in the previous Ovation sponsored study on psychosis in PD which, in the opinion of the Investigator, was probably or certainly connected to the use of the melperone; 3. History of serious cardiovascular conditions (including, for simplicity but not limited to, class IV angina or class IV heart failure) and/or of risk factors for Torsade de pointes (Tdp) (including for simplicity but not limited to, current treatment for hypokalemia or family history of long QT syndrome); 4. During the previous Ovation sponsored study on psychosis in PD, the patient had an ECG with a corrected QT interval with the Bazett formula, of more than 450 msec if female, 430 msec if male. If the patient had an ECG greater than 450 msec if female, or 430 if male, then he/she may take part in the new study as long as: a. the patient did not have a value of QTc greater than 500 msec during the double-blind study; b. the patient's QTc was ≤450 msec if female, or ≤430 msec if male, at Day 43 (for patients under treatment with 4 ml of experimental drug) or at the Final Visit of the double-blind study. i. Patients who have had a QTc >450 msec if female, or >430 msec if male at Day 43 or at the Final Visit may be eligible in the new study if they gradually reduce the dose of the drug to 0 ml, return to repeat the ECG and this new ECG shows a QTc ≤450 msec if female, or ≤430 msec if male. 5. Patients requiring therapy with an alpha-agonist agent. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Assessment of effectiveness The primary effectiveness endpoint will be the change in the SAPS score. Other effectiveness endpoints may be other neuropsychiatric scales, like the NPI total score and relevant items and subscales, and UPDRS and relevant subscales.
Safety Safety assessments include the analysis of adverse events, serious adverse events, physical examination, calculation of the Body Mass Index (BMI), laboratory test values, vital signs and ECG intervals. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 2 |